title: Treatment with a CRH-1-receptor antagonist (R121919) does not affect weight or plasma leptin concentration in patients with major depression.
abstract: Weight gain during treatment with psychotropic drugs is frequently observed and is assumed to be responsible for non-compliance and for an elevated risk to develop a number of somatic co-morbidities including cardiovascular disorders and type 2 diabetes. Absence of weight inducing effects is therefore a major objective for the development of new compounds. Recently, R121919, the first corticotropin releasing hormone receptor 1 (CRH1R) antagonist, was tested in major depression. Clinical efficacy, safety, and tolerability of this compound could be demonstrated. Since CRH is discussed to be involved in the regulation of appetite and weight, directly and via interaction with leptin, CRH1R antagonists are suspected to influence body weight. Effects of 30 days of treatment with the CRH1R antagonist R121919 on weight and leptin levels in 20 patients suffering from major depression were investigated. No significant weight changes during treatment with R121919 were observed. Furthermore, noeffects on plasma leptin concentrations were found. We conclude that treatment with the CRH1R antagonist R121919 does not affect weight or plasma leptin concentrations in patients with major depression. Together with previous findings indicating safety, tolerability, and clinical efficacy CRH1R antagonists are highly promising as a new treatment option in depression.
authors.affiliation: Max Planck Institute of Psychiatry, Kraepelinstr. 2-10, D-80804 Munich, Germany. Heike.Kuenzel@balgrist.ch
authors.forename: Heike E
authors.initials: HE
authors.lastname: Künzel
authors.forename: Marcus
authors.initials: M
authors.lastname: Ising
authors.forename: Astrid W
authors.initials: AW
authors.lastname: Zobel
authors.forename: Thomas
authors.initials: T
authors.lastname: Nickel
authors.forename: Nibal
authors.initials: N
authors.lastname: Ackl
authors.forename: Annette
authors.initials: A
authors.lastname: Sonntag
authors.forename: Florian
authors.initials: F
authors.lastname: Holsboer
authors.forename: Manfred
authors.initials: M
authors.lastname: Uhr
mesh_terms: D000328:Adult; D003865:Major Depressive Disorder / Q000188:drug therapy*; D003924:Diabetes Mellitus, Type 2 / Q000139:chemically induced; D005260:Female; D006801:Humans; D020738:Leptin / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011743:Pyrimidines / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use*; D018019:Receptors, Corticotropin-Releasing Hormone / Q000037:antagonists & inhibitors; D054411:Receptors, Leptin; D012307:Risk Factors; D015430:Weight Gain
chemical_list: C515448:LEPR protein, human; D020738:Leptin; D011743:Pyrimidines; C412383:R 121919; D018019:Receptors, Corticotropin-Releasing Hormone; D054411:Receptors, Leptin